Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P412: Efficacy and safety of additional autologous platelet-rich stroma in transanal mucosal advancement flap repair of complex cryptoglandular anal fistulas

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Arkenbosch*1, O. van Ruler2, W. Deijl2, J. Stevens3, A. de Vries4, J. van der Woude4, E. de Graaf2, R. Schouten1,2

1Erasmus Medical Center, Department Colorectal surgery, Rotterdam, The Netherlands, 2Ijsselland Hospital, Department Colorectal surgery, Capelle a/d Ijssel, The Netherlands, 3Bergman Clinics, Department Reconstructive surgery, Bilthoven, The Netherlands, 4Erasmus Medical Center, Department Gastroenterology, Rotterdam, The Netherlands

P413: A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

P. S. Dulai*1, A. Amiot2, L. Peyrin-Biroulet3, S. Singh1, M. Serrero4, V. Jairath5, J. Filippi6, B. Pariente7, E. V. Loftus Jr8, X. Roblin9, S. Kane8, A. Buisson10, C. A. Siegel11, Y. Bouhnik12, W. J. Sandborn1, K. Lasch13, M. Rosario13, B. G. Feagan5, D. Bojic14, C. Trang-Poisson15, B. Shen16, R. Altwegg17, B. E. Sands18, J-F. Colombel18, F. Carbonnel19, M. Bohm20, D. Hudesman21, A. Bourrier22, D. Lukin23, GETAID OBSERV-IBD and VICTORY Cohorts Collaboration1

1University of California San Diego, La Jolla, CA, USA, 2Henri Mondor University Hospital, Creteil, France, 3University of Lorraine, Nancy, France, 4Aix-Marseille University, Marseille, France, 5University of Western Ontario, London, ON, Canada, 6Nice University Hospital, Nice, France, 7Claude Huriez Hospital, Lille, France, 8Mayo Clinic, Rochester, MN, USA, 9University Hospital of Saint-Etienne, Saint-Etienne, France, 10Estaing University Hospital, Clermont-Ferrand, France, 11Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, 12Beaujon Hospital, Clichy, France, 13Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA, 14Takeda Pharmaceuticals International AG, Zurich, Switzerland, 15University Hospital of Nantes, Nantes, France, 16Cleveland Clinic Foundation, Cleveland, OH, USA, 17University Hospital of Montpellier Saint-Eloi, Montpellier, France, 18Icahn School of Medicine at Mount Sinai, New York, NY, USA, 19Bicetre University Hospital, Paris, France, 20Indiana University, Indianapolis, IN, USA, 21New York University (NYU), New York, NY, USA, 22Saint-Antoine University Hospital, Paris, France, 23Montefiore Medical Center, New York, NY, USA

P414: Ustekinumab endoscopic response at Week 16 is associated with early normalisation of faecal calprotectin after induction

ECCO '19 Copenhagen

Year: 2019
Authors:

R. W. M. Pauwels*1, A. C. de Vries1, J. C. Goet1, N. S. Erler2, C. J. van der Woude1

1Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2Erasmus MC, Department of Biostatistics, Rotterdam, The Netherlands

P415: Predictive factors of a subsequent ano-perineal abscess in patients with fistulising ano-perineal Crohn’s disease in remission

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Rivière1, A. Malian1, D. Bouchard2, F. Pigot2, M. Eleouet-Kaplan2, C. Favreau-Weltzer2, F. Poullenot1, D. Laharie1

1Bordeaux University Hospital, Gastroenterology and nutrition, Bordeaux, France, 2Bagatelle Health Center, Proctology, Bordeaux, France

P416: Faecal calprotectin can predict mucosal healing in patients with inflammatory bowel diseases treated with vedolizumab: a prospective single-centre study

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Bertani*1, L. Ceccarelli2, M. G. Mumolo2, R. Tedeschi1, E. Albano1, G. Tapete1, G. Baiano Svizzero1, N. De Bortoli1, A. Ricchiuti2, M. Bellini1, S. Marchi1, F. Costa2

1University of Pisa, Department of New Technologies and Translational Sciences in Medicine And Surgery, Pisa, Italy, 2Pisa University Hospital, Department of General Surgery and Gastroenterology, Pisa, Italy

P417: 10 years of endoscopic therapy of symptomatic Crohn’s disease stenoses: a retrospective analysis of long-term results

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Aichinger1, K. Rothfuss1, M. Koch1, E. F. Stange1, J. G. Albert1, C. Schäfer1

1Robert Bosch Hospital, Department of Gastroenterology, Hepatology and Endocrinology, Stuttgart, Germany

P418: Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Higgins*1, D. Ginsburg2, K. Gilder3, K. Gilder3, B. Walsh3, B. English3, S. Turner3, P. Klassen3, S. Hanauer4, C. Barish5, B. Yacyshyn6

1University of Michigan, Internal Medicine, Ann Arbor, USA, 2Multicare Institute, Tacoma, USA, 3Arena Pharmaceuticals, San Diego, USA, 4Northwestern University, Chicago, USA, 5University of North Carolina, Chapel Hill, USA, 6University of Cincinnati, Cincinnati, USA

P419: Outcomes for patients with severe acute ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Shivakumar*1, R. Grant2, R. Lynch2, T. Manship3, F. Jagger3, J. Satsangi4, G. T. Ho3, N. Plevris3, C. Lees5, I. Arnott3

1University of Edinburgh, Edinburgh, UK, 2Royal Infirmary of Edinburgh, Edinburgh, UK, 3Westen General Hospital, Edinburgh, UK, 4University of Oxford, Oxford, UK, 5Western General Hospital, Edinburgh, UK

P420: Correlation between Infliximab trough levels and endoscopic activity in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Bernardo*1, S. Fernandes1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Marinho1

1Hospital Santa Maria, CHLN, Gastrenterology, Lisbon, Portugal

P421: Effects of combination therapy in inflammatory bowel disease: how long should we keep concomitant immunomodulators?

ECCO '19 Copenhagen

Year: 2019
Authors:

J. C. Silva*1, A. P. Silva1, A. Rodrigues1, C. Fernandes1, A. Ponte1, J. Rodrigues1, M. Sousa1, A. C. Gomes1, J. Carvalho1

1Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de Gaia, Portugal

P422: Immunogenicity of a proposed adalimumab biosimilar, FKB327, and the reference product in patients with rheumatoid arthritis

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Alten*1, C. Markland2, K. Kawakami3, M. Boyce4, F. Casty5, R. Muniz5, M. C. Genovese6

1Schlosspark Klinik, University Medicine Berlin, Head of Department of Internal Medicine II, Rheumatology, Clinical Immunology, Osteology Director of Rheumatology Research Center, Berlin, Germany, 2NDA Group, Leatherhead, Surrey, UK, 3Fujifilm Kyowa Kirin Biologics Co., Ltd., Clinical Development Department, Tokyo, Japan, 4Hammersmith Medicines Research, London, UK, 5Mylan Inc., Global Medical Affairs, Canonsburg, USA, 6Stanford University School of Medicine, James W. Raitt Endowed Professor of Medicine Co-Chief Division of Immunology and Rheumatology, Palo Alto, USA

P423: Comparative efficacy of anti-tumour necrosis factor agents and vedolizumab in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Subramanian*1, R. Davis1, P. MacParland1, S. Dodd2, D. Storey1, C. Probert1, P. Collins1, T. Skouras1, A. Steel1, E. Derbyshire1, M. Dibb1

1Royal Liverpool University Hospital, Liverpool, UK, 2Institute of Translational medicine, Department of Biostatistics, Liverpool, UK

P424: Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Calafat*1, M. Mañosa1,2, E. Ricart2,3, E. Iglesias4, M. Calvo5, F. Rodríguez-Moranta6, C. Taxonera7, P. Nos2,8, F. Mesonero9, M. Martín-Arranz10, M. Mínguez11, J. P. Gisbert2,12, S. García-López13, R. de Francisco14, F. Gomollón2,15, X. Calvet2,16, E. García-Planella17, M. Rivero18, J. Martínez-Cadila19, F. Argüelles20, L. Arias21, M. Cimavilla22, Y. Zabana2,23, F. Cañete1,2, E. Cabré1,2, E. Domènech1,2, ENEIDA Registry of GETECCU1

1Hospital Universitari Germans Trias i Pujol, Gastroenterology Department, Badalona, Spain, 2CIBERehd, Madrid, Spain, 3Hospital Clínic, Barcelona, Spain, 4Hospital Reina Sofía, Córdoba, Spain, 5Hospital Puerta de Hierro, Majadahonda, Spain, 6Hospital de Bellvitge, L'Hospitalet del Llobregat, Spain, 7Hospital Clínico San Carlos, Madrid, Spain, 8Hospital La Fe de Valencia, Valencia, Spain, 9Hospital Ramón y Cajal, Madrid, Spain, 10Hospital La Paz, Madrid, Spain, 11Hospital Clínico de Valencia, Valencia, Spain, 12Hospital Universitario de La Princesa, Madrid, Spain, 13H.U. Miguel Servet, Zaragoza, Spain, 14H.U. Central de Asturias, Oviedo, Spain, 15H. Clínico Lozano Blesa, Zaragoza, Spain, 16H. Parc Taulí, Sabadell, Spain, 17H. Santa Creu i Sant Pau, Barcelona, Spain, 18H.U. Marqués de Valdecilla, Santander, Spain, 19Complexo H.U. de Vigo, Vigo, Spain, 20H. Virgen de la Macarena, Sevilla, Spain, 21H.U. Burgos, Burgos, Spain, 22H. Río Hortega, Valladolid, Spain, 23H. Mútua de Terrassa, Terrassa, Spain

P425: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of ustekinumab

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Farrag*1,2, M. Rohlfs3, J. Ruppert3, F-P. Armbruster3, J. Stein1,2

1Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 2DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 3Immundiagnostik AG, Bensheim, Germany

P426: Lympocytosis in patients with inflammatory bowel disease treated with anti-TNFa agents: is it significant?

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Soufleris*1, N. Kafalis1, M. Charalampidis1, K. Fasoulas1, I. Pilpilidis1, G. Lazaraki1, D. Tzilves1, D. Markala2

1Theagenion CHT, Gastroenterology Department, Thessaloniki, Greece, 2Theagenion CHT, Dir Haematology Lab, Thessaloniki, Greece

P427: Impact of curcuma longa on clinical activity and inflammatory markers in patients with active ulcerative colitis: a double-blind randomised placebo-controlled trial

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Kumar1, U. Dutta1, J. Shah*1, P. Singh1, C. Vaishnavi1, K. K. Prasad1, K. Singh1

1PGIMER, Gastroenterology, Chandigarh, India

P428: Long-term outcomes of endoscopic ballon dilation for small-bowl strictures using double balloon enteroscopy in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Takeda*1, F. Hirai1, N. Takatsu1, M. Kishi2, T. Beppu2, K. Yao3, T. Ueki2

1Fukuoka University Chikushi Hospital, IBD Center, Fukuoka, Japan, 2Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan, 3Fukuoka University Chikushi Hospital, Department of Endoscopy, Fukuoka, Japan

P429: Factors associated with weight gain in patients treated with anti-TNF-α for inflammatory bowel disease: a cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Haas1, V. Abitbol2, T. Paupard3, S. Chaussade2, S. Nahon*1

1GHI Le Raincy-Montfermeil, Gastroenterology, Montfermeil, France, 2Hopital Cochin, Paris, Gastroenterology, Paris, France, 3Hopital de Dunkerque, Gastroenterology, Dunkerque, France

P430: European clinician perspective on withdrawing immunosuppression

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Boyapati1, S. R. Fehily*2, N. S. Ding3

1Monash Medical Centre, Gastroenterology, Melbourne, Australia, 2St Vincent's Hospital, Gastroenterology, Melbourne, Australia, 3St Vincent’s Hospital, Gastroenterology, Melbourne, Australia

P431: Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab

ECCO '19 Copenhagen

Year: 2019
Authors:

M. B. Ruiz-Argüello*1, A. Maguregui1, A. Martínez1, D. Nagore1

1Progenika Biopharma-Grifols, Derio, Spain